Imagine your body's instructions for making proteins are like a recipe book, but in cancer, some pages are cut and pasted incorrectly. This project found a way to spot these 'typos' and use them as targets. By teaching the immune system to recognize these specific mistakes, they can create custom vaccines that hunt down cancer cells while leaving healthy ones alone.
Approximately 60% of the 8 million annual cancer patients in Europe lack approved immunotherapy options, particularly those with splicing factor mutations in leukemia and melanoma.
A pipeline for identifying splicing-derived antigens, mRNA-formulated vaccines, TCRs for tumor killing, and a scalable LNP delivery platform.
If you are a vaccine developer dealing with low response rates in solid tumors — this project developed mRNA-formulated vaccines targeting splice-derived neo-antigens that activate T-cells and kill tumor cells.
If you are a biotech firm dealing with refractory leukemia or melanoma — this project developed T-cell receptors (TCRs) and CRISPR-Cas9 guides that modulate RNA splicing to enhance immune effector cell activity.
If you are a delivery company dealing with inefficient RNA transport — this project developed optimized lipid nanoparticle (LNP) formulations that achieve highly efficient transfection of dendritic cells and macrophages.
Based on available project data, specific pricing or cost-per-dose information is not provided; however, the project received an EU contribution of EUR 5,999,381 for development.
The project developed LNP formulations described as a scalable and reproducible platform for delivering RNA payloads, suggesting a path toward industrial production.
Based on available project data, specific licensing terms are not listed, but the consortium includes 4 industry partners and 2 SMEs, indicating a structure for commercial translation.
The project was implemented over a 36-month period from June 2022 to May 2025.
The project uses high-throughput sequencing of patient samples (AML, MDS, and uveal melanoma) to identify antigens, which are then used to create personalized vaccines.
The consortium is well-balanced for commercialization, featuring 13 partners across 6 countries. With a 31% industry ratio (including 4 industry partners and 2 SMEs), there is a strong bridge between the 5 universities and 4 research institutes and the market, specifically targeting the translation of RNA biology into clinical products.
Contact Hadassah Medical Organization in Israel
Contact us to explore licensing opportunities for the LNP delivery platform or splice-variant TCRs.
